{"id":34478,"date":"2026-06-03T07:11:09","date_gmt":"2026-06-03T07:11:09","guid":{"rendered":"https:\/\/www.europesays.com\/japan\/34478\/"},"modified":"2026-06-03T07:11:09","modified_gmt":"2026-06-03T07:11:09","slug":"global-biopharma-leaders-meet-japanese-pm-to-reinforce-action-for-retaining-japans-leadership-in-life-sciences","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/japan\/34478\/","title":{"rendered":"Global biopharma leaders meet Japanese PM to reinforce action for retaining Japan\u2019s leadership in life sciences"},"content":{"rendered":"<p>\t\t\t\t\t\tGlobal biopharma leaders meet Japanese PM to reinforce action for retaining Japan\u2019s leadership in life sciences<\/p>\n<p class=\"float-left\">June 3, 2026 | Wednesday | News<\/p>\n<p>\t\t\t\t\t\t\tBiopharmaceutical companies have invested \u00a514 trillion in research and development in Japan<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/japan\/wp-content\/uploads\/2026\/06\/screenshot_3_6_2026_121211_www_bing_com-27733.jpeg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"image credit- shutterstock\"\/><\/p>\n<p class=\"mt-3 text-center\">image credit- shutterstock<\/p>\n<p style=\"text-align: justify;\">A delegation of over 20 global pharmaceutical leaders from top American, Japanese and European biopharmaceutical companies met \u00a0with Prime Minister (PM) Sanae Takaichi to reinforce the action needed for Japan to grow its leadership in life sciences.<\/p>\n<p style=\"text-align: justify;\">Over the past decade, biopharmaceutical companies have invested \u00a514 trillion in research and development in Japan, have developed more than 1,200 new medicines, and directly support over 140,000 high\u2011skilled jobs nationwide. This places innovative pharmaceuticals among Japan\u2019s most R&amp;D\u2011intensive and high\u2011productivity sectors, supporting advanced manufacturing and highly skilled employment.<\/p>\n<p style=\"text-align: justify;\">However, longstanding policy changes alongside growing global competition, are contributing to Japan being one of the major pharmaceutical markets experiencing a structurally declining share of global biopharmaceutical R&amp;D and investment, with early\u2011stage pipelines and clinical trial activity increasingly shifting elsewhere. Most Favoured Nation (MFN) policies risk compounding this, placing Japan at a growing competitive disadvantage.<\/p>\n<p style=\"text-align: justify;\">Global pharmaceutical leaders also shared evidence demonstrating the urgency of reform to safeguard patient access in Japan. Between 2014 and 2023, 245 new medicines launched in the United States or Europe became unavailable in Japan.<\/p>\n<p style=\"text-align: justify;\">Changes to how innovative medicines are valued \u2013 including repeated revisions to drug pricing rules \u2013 have also contributed to a widening gap between the medicines available to Japanese patients, and those available to patients in other countries.<\/p>\n<p style=\"text-align: justify;\">Global pharmaceutical leaders highlighted that increasing government expenditure for innovative medicines, is core to addressing this gap.<\/p>\n<p style=\"text-align: justify;\">Biopharmaceutical CEOs Roundtable (BCR)\u00a0Vice Chair, Hiroyuki Okuzawa, Chief Executive Officer Daiichi Sankyo, said,\u00a0\u201cJapan remains one of the traditional homes of pharmaceutical innovation, and will continue to be central to the future strength of Japan. Continued innovation will be critical in successfully tackling demographic change, emerging health challenges and evolving global risks.&#8221;<\/p>\n<p style=\"text-align: justify;\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Global biopharma leaders meet Japanese PM to reinforce action for retaining Japan\u2019s leadership in life sciences June 3,&hellip;\n","protected":false},"author":2,"featured_media":34479,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[26205,8,17,3261,7995,2848],"class_list":["post-34478","post","type-post","status-publish","format-standard","has-post-thumbnail","category-japan","tag-big-pharma","tag-japan","tag-japanese","tag-leadership","tag-life-sciences","tag-pm"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/34478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/comments?post=34478"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/34478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media\/34479"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media?parent=34478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/categories?post=34478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/tags?post=34478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}